Richmond, Va. (Aug. 5, 2008) — Researchers at the Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine have published findings that implicate a new chemoprevention gene therapy (CGT) for preventing and treating pancreatic cancer, one of the most lethal and treatment-resistant forms of cancer.
In the July issue of Molecular Cancer Therapeutics, the researchers showed that combining a dietary agent with a gene-delivered cytokine effectively eliminates human pancreatic cancer cells in mice displaying sensitivity to these highly aggressive and lethal cancer cells.
Cytokines are a category of proteins that are secreted into the circulation and can affect cancer cells at distant sites in the body, including metatases. The cytokine used in this study was melanoma differentiation associated gene-7/interleukin-24, known as mda-7/IL-24.
The dietary agent, perillyl alcohol (POH), was combined with mda-7/IL-24, which is already used in other cancer treatments. POH is found in a variety of plants, including citrus plants, and has been well-tolerated by patients who have received it in clinical studies.
The results indicated that the CGT approach not only prevented pancreatic cancer growth and progression, but it also effectively killed established tumors, thereby displaying profound chemopreventive and therapeutic activity.
Paul B. Fisher, Ph.D., was principal investigator of the study, which was supported by the National Institutes of Health and the Samuel Waxman Cancer Foundation. Fisher, who recently joined VCU from Columbia University, is professor and interim chair of VCU's department of human and molecular genetics; holds the Thelma Newmeyer Corman chair in cancer research at Massey; and is director of the VCU Institute of Molecular Medicine.
"Our hypothesis was that certain non-toxic dietary agents that had the ability to promote reactive oxygen species (ROS) would break down pancreatic cancer cell resistance to therapy following administration of mda-7/IL-24 and be safe for human use," said Fisher. "We are very excited at the prospect of this chemoprevention gene therapy as a means of both preventing and treating pancreatic cancer, and it has significant potential to move rapidly into human clinical trials."
Pancreatic cancer has a five-year survival rate of less than 5 percent, and currently there is no effective chemotherapy or radiation therapy for it. About 37,000 new cases are diagnosed in the United States each year.
To read an abstract of the study, visit http://mct.aacrjournals.org/cgi/content/abstract/7/7/2042.
Other researchers on this study include Irina V. Lebedeva, Mohammad Athar and Lejuan Chatman from the Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons in New York; Zhao-zhong Su, Nichollaq Vozhilla, Devanand Sarkar and Paul Dent, researchers of the VCU Massey Cancer Center who, along with Fisher, hold academic positions in the departments of Human and Molecular Genetics, Biochemistry and Molecular Biology and the VCU Institute of Molecular Medicine.
About the VCU Massey Cancer Center: The VCU Massey Cancer Center is one of 63 National Cancer Institute-designated institutions that leads and shapes America's cancer research efforts. Working with all kinds of cancers, the Center conducts basic, translational and clinical cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. It offers more clinical trials than any other institution in Virginia, serving patients in Richmond and in four satellite locations. Its 1,000 researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately to cure cancer. Visit Massey online at www.massey.vcu.edu or call 1-877-4-MASSEY.
About VCU and the VCU Medical Center: Virginia Commonwealth University is the largest university in Virginia and ranks among the top 100 universities in the country in sponsored research. Located on two downtown campuses in Richmond, VCU enrolls nearly 32,000 students in 205 certificate and degree programs in the arts, sciences and humanities. Sixty-five of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 15 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation's leading academic medical centers. For more, see www.vcu.edu.
Molecular Cancer Therapeutics